GlassScriptPhysician profile
James F Lee
NPI 1366476970
$4,926.80
in general payments reported to CMS, 2019-2025
33 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,562 · 2020: $830 · 2021: $1,650 · 2022: $599 · 2023: $53.31 · 2024: $66.58 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $640.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $567.11 | 2019-2022 | |
| Novo Nordisk INC | $550.43 | 2019-2022 | |
| Lilly USA, LLC | $505.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $343.85 | 2021-2023 | |
| Pfizer INC. | $314.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $263.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.35 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $186.96 | 2020-2021 | |
| Abbott Laboratories | $178.18 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $171.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.78 | 2019-2022 | |
| Abbvie INC. | $126.81 | 2021-2024 | |
| Amarin Pharma, INC. | $123.97 | 2019 | |
| Hologic Sales and Service, LLC | $82.63 | 2019-2025 | Aptima |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.14 | 2019-2021 | |
| Amgen INC. | $75.23 | 2019-2020 | |
| Intra-Sana Laboratories | $39.30 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Otsuka America Pharmaceutical, INC. | $37.98 | 2019 | |
| Ucb, INC. | $34.07 | 2019 | |
| Boston Scientific Corporation | $26.46 | 2025 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $23.53 | 2022 | |
| Sanofi Pasteur INC. | $22.97 | 2019 | |
| Allergan, INC. | $22.50 | 2020 | |
| Forte Bio-Pharma LLC | $19.74 | 2020 | |
| Genentech USA, INC. | $19.01 | 2020 | |
| Rgh Enterprises LLC | $17.76 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.19 | 2021 | |
| Gilead Sciences, INC. | $16.05 | 2021 | |
| Cranial Technologies, INC | $15.10 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.91 | 2022 | |
| Janssen Biotech, INC. | $8.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.